<i>TP</i>53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma

Journals Menu

Follow SCIRP

ISSN Print: 2158-284X
ISSN Online: 2158-2882
www.scirp.org/journal/ijcm
E-mail: ijcm@scirp.org

"TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma"
written by Ligia Richter, Marcelo Buzzi, Carmela Dantas-Barbosa,
published by International Journal of Clinical Medicine, Vol.4 No.12A, 2013

has been cited by the following article(s):

[1]	Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
	2019

[2]	TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data
	Disease Markers, 2016

[1]	Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma Journal of Orthopaedic Research, 2019 DOI:10.1002/jor.24227

[2]	Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma Journal of Orthopaedic Research, 2019 DOI:10.1002/jor.24227

[3]	TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data Disease Markers, 2016 DOI:10.1155/2016/4639575

Follow SCIRP